疏肝解瘀汤联合恩替卡韦治疗慢性乙肝的临床分析  

Clinical analysis of Shuganjieyu Decoction combined with entecavir in the treatment of chronic hepatitis B

作　　者：彭春悦 Peng Chun-yue(Department of Hepatology,Dengzhou Hospital of Traditional Chinese Medicine,Dengzhou 474150,Henan,China)

机构地区：[1]邓州市中医院肝病科,河南邓州474150

出　　处：《四川生理科学杂志》2024年第8期1783-1786,共4页

摘　　要：目的:探讨疏肝解瘀汤与恩替卡韦联合治疗方案对慢性乙肝的临床应用效果。方法:选取2021年1月-2023年5月邓州市中医院肝病科收治的168例慢性乙肝患者,按随机数字表法分对照组和试验组,各84例。对照组采用恩替卡韦治疗,试验组在此基础上加以疏肝解瘀汤。比较两组治疗效果、中医证候积分、肝功能指标、病毒学指标及不良反应发生情况。结果:试验组总有效率(97.62%)高于对照组(86.90%)(P<0.05);治疗后,试验组中医证候积分、血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)及总胆红素(TBil)低于对照组(P<0.05);治疗后,试验组乙型肝炎病毒表面抗原(HBsAg)及乙肝病毒脱氧核糖核酸(HBV-DNA)低于对照组,HBV-DNA转阴率(97.62%)高于对照组(89.29%)(P<0.05);两组不良反应发生率比较,差异不显著(P>0.05)。结论:对慢性乙肝患者采用疏肝解瘀汤与恩替卡韦联合治疗,能有效减轻患者中医证候积分,优化肝功能指标,有效抑制乙型肝炎病毒复制,促进HBV-DNA转阴,提高整体疗效。Objective:To explore the clinical effect of Shuganjieyu Decoction and entecavir combination therapy on chronic hepatitis B.Methods:168 patients with chronic hepatitis B admitted to Department of Hepatology of Dengzhou Hospital of Traditional Chinese Medicine from January 2021 to May 2023 were selected and divided into the control group and the test group according to the random number table,84 patients in each group.The control group was treated with Entecavir,while the experimental group was treated with Shuganjieyu Decoction on this basis.The treatment effects,traditional Chinese medicine syndrome scores,liver function indicators,virological indicators,and incidence of adverse reactions were compared in both groups.Result:Compared with control group,the total effective rate of the experimental group(97.62%)was higher(86.90%)(P<0.05).The TCM syndrome scores,serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),and total bilirubin(TBil)of experimental group was lower than the control group after treatment(P<0.05).After treatment,compared with control group,the levels of hepatitis B virus surface antigen(HBsAg)and hepatitis B virus deoxyribonucleic acid(HBV-DNA)in the experimental group were lower,and compared with control group(89.29%),the HBV-DNA conversion rate was higher(P<0.05).The incidence of adverse reactions between the two groups was not significantly different(P>0.05).Conclusion:The combination treatment of Shuganjieyu Decoction and entecavir for chronic hepatitis B patients can effectively reduce the TCM syndrome score of patients,optimize liver function indicators,effectively inhibit the replication of hepatitis B virus,promote the negative transformation of HBV DNA,and improve the overall efficacy.

关 键 词：疏肝解瘀汤 恩替卡韦 慢性乙型肝炎 疗效 肝功能 

分 类 号：R512.62[医药卫生—内科学]